California’s Medicaid grants TGI participating provider status effective June 5, 2023, providing Medi-Cal patients access to non-invasive rejection testing with the TruGraf® blood gene expression test and the Viracor TRAC® (Transplant Rejection Allograft Check), donor-derived cell-free DNA test.

November 2023

FRAMINGHAM, MA –Transplant Genomics, Inc (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is excited to announce the decision by California’s Department of Health Care Services to approve TGI as a participating provider. This establishes a pathway of access of TruGraf, TGI’s proprietary gene expression test for subclinical acute rejection and Viracor TRAC, it’s donor-derived cell-free DNA test to determine active rejection, to Medi-Cal’s transplant patient population. Medi-Cal, California’s Medicaid Program, covers more than one-third of the state’s population. Participating provider status was confirmed effective June 5, 2023.

TruGraf is the first blood gene expression test approved by CMS/Medicare for kidney transplant rejection. TruGraf offers early detection of “silent” subclinical acute rejection in kidney transplant patients with stable kidney function before organ injury and acute rejection begins. This novel biomarker test offers transplant patients a non-invasive option for otherwise painful biopsy procedures, leading to the detection of subclinical chronic rejection and an improved quality of life. Likewise, Viracor TRAC, approved by CMS/Medicare, offers early detection of active kidney rejection.

Transplant Genomics is thrilled that California’s Department of Health Care Services has extended participating provider status to TGI, making TruGraf and Viracor TRAC more easily accessible for their 5.3 million eligible residents. TGI is committed to working in partnership with payors to ensure that as many patients as possible can benefit from our non-invasive approach to improving transplant health.

Notes to Editors:

For more information:

Brian Tees

Transplant Genomics, Inc.

Brian.Tees@viravor.eurofinsus.com

About Transplant Genomics, Inc.

Eurofins Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family of companies, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. Our flagship product is TruGraf, the only non-invasive blood test approved by CMS that offers early detection of “silent” subclinical acute rejection in kidney transplant recipients with stable graft function. Test services are offered through TGI’s CLIA laboratory in Lenexa, Kansas. TGI was acquired by Eurofins Scientific in 2019.

Learn more about Transplant Genomics at: http://www.transplantgenomics.com

For more information, please visit www.eurofins.com or contact:

Investor Relations

Eurofins Scientific SE

Phone: +32 2 766 1620

E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins network of companies believes that it is the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

About the Department of Health Care Services

DHCS is the backbone of California’s healthcare safety net, helping millions of low-income and disabled Californians each and every day.

The mission of DHCS is to provide Californians with access to affordable, integrated, high-quality health care, including medical, dental, mental health, substance use treatment services and long-term care. Our vision is to preserve and improve the overall health and well-being of all Californians.

DHCS funds health care services for more than 15.4 million Medi-Cal beneficiaries. About one-third of Californians receive healthcare services financed or organized by DHCS, making the Department the largest healthcare purchaser in California. Our success is made possible only through collaboration with the federal government and other state agencies, counties, and partners as we invest nearly $124 billion for the care of low-income families, children, pregnant women, seniors, and persons with disabilities.

Among the programs administered by DHCS, some of which are mandated by the federal government and others required by state law, are California Children’s Services; Child Health and Disability Prevention program; Genetically Handicapped Persons Program; Newborn Hearing Screening Program; Family Planning, Access, Care, and Treatment program; Program of All-Inclusive Care for the Elderly; Every Woman Counts; and Coordinated Care Management. DHCS also administers programs for underserved Californians, including farmworkers and American Indian communities.

DHCS is constantly seeking to improve its services. For example, to improve access to services and ensure we spend tax dollars efficiently, more than 83 percent of our beneficiaries receive care from a Medi-Cal managed care plan. Under these models, access to health care is easier and the quality of care is improved.

DHCS is a dynamic Department with ambitious goals and talented, committed employees. We work hard every day to fulfill our vital responsibility to support the delivery of quality health care to Californians. Going forward, we will continue to use our state’s tax dollars as effectively as possible while finding opportunities to improve Californians’ health and the healthcare delivery system of our Golden State.

Learn more about the DHCS at: https://www.dhcs.ca.gov/